GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...

July 17 (Reuters) - GSK will halt development of its experimental drug to treat refractory chronic cough after the therapy ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

GSK on ​Friday said ‌it had decided ​not ​to develop its ⁠experimental ​drug to ​treat refractory chronic cough ​further ​after it did ‌not ⁠meet one of its ​main ​goals ⁠in a ​late-stage ​trial.

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

U.S. stock futures dip amid AI chip selloff. Here are some stocks to watch on the day.

GSK (GSK) stock slips as the company discontinues a cough therapy added from its $2B Bellus Health acquisition following a ...

Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly ...

Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic ...

Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

GSK signed an exclusive licence deal with Hansoh Pharma in 2023, laying out up to $1.71bn in an upfront payment plus ...